Get started

CUV

Clinuvel (CUV) set up for the next 200-350% run-up!Chart pattern: Since 2014 a regular chart-pattern can be observed in the Clinuvel ( CUV ) chart. After one year of a strong run-up (mostly starting in late February), the stock reaches a local peak (around Sept-Nov) and starts a correction (around -35% to -50%), followed by a longer sideways consolidation. Then the year after late Feb the next run-up starts. After the FDA approval in October 2019 the stock peaked, followed again by a strong and long correction and consolidation. Currently, a new upmove started end of February 2021, bringing the stock from its recent correction low already up by 40% (20 AUD to 28 AUD). Assuming the regluar pattern repeats, the new upmove has already started end of February and should bring the stock up to 60-86 AUD (200-330%) by autumn 2021. Fundamental support of the coming run-up Clinuvel is an innovative Biotech-Company, based in Melbourne Australia (ASX listed) and the world leader in Melanocortin-Hormones. Clinuvel offers the product "Scenesse" (Afamelanotide), which is approved in Europe since 2014, in USA since 2019 and in Australia and Israel since 2020. The company has no debts and is highly profitable. There are several fundamental accelerators and good news to support a coming up-move: - Continues expansion of the product in Europe (more and more countries are approved and reimbursed) - Massive revenue growth expected in the USA, as the infrastructur for the distribution of Scenesse has been established now - New Marketing and brand building initiatives - New studies in place for label extension of the product -> Vitiligo Phase 3 program to be started soon (Clinuvel is in final alignment with the FDA) (billon dollar market) -> Ischemic stroke program: First study to be started shortly (billion dollar market) -> XP study to proof DNA repair capabilities of Scenesse -> Launch of OTC cosmetic products for mass market, with active ingredients for skin tanning (billion dollar market) Overall, the management of the company is highly bullish to reach the set goals.
ASX:CUVLong
by TBech
2
CUV: ASX - CLINUVEL PHARMACEUTICALSFrom September 2018 through to May 2019 this stock was in a re-accumulation phase. You can see there was a sell off in September when supply it the market and the stock pulled back. From November the stock hit support and from there we started making higher lows. We took at the top of the trading range in late February where we a sign of strength. The stock was sold into that rise and we pulled back again. It broke back down through the top of the range but bounced back very quickly. A definite last point of support before mark up. Completing the re-accumulation. The stock ran well from May to July. The first sign that there may be a significant pull back at some stage was the steepness of how it moved higher. We did see a large amount of supply come in - the most we had ever seen. Interestingly we only had a small pull back on lighter volume. The stock moved higher again with $40 in its sights. Look at the supply that came in June. A definite buying climax. A lot of retail traders were sucked into this one at that stage and the professionals were selling into the up move. This time we saw a significant pull back. A certain first sign of weakness. Price took out the low before the high (Where demand came in) and it looked as if it was forming a distribution range to move lower. The news changed that. It looks like further distribution then took place, which negated the need to move the stock sideways for a considerable time. I believe this stock was heavily accumulated back in the $0 - $5 range and this has been a very long and patient campaign. Stock was sold at approx $22, $29, $34, $38 and finally $44. A very successful campaign. $23.65 is the key level now. The low before the extreme move higher. If that is taken out, it could be heading a lot lower. If it can hold that level and consolidate and build another accumulation range, it may move higher. Right now its a holding pattern. Happy New Years!
ASX:CUV
by AussieWyckoff